Bafna Pharmaceuticals Fair Value
Bafna Pharmaceuticals (BAFNAPH) average fair value is ₹323.66 across 3 valuation models — P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, vs a current market price of ₹193.97 (+66.86%), fair value range ₹18.55–₹697.42. Check BAFNAPH market cap trends to track the company's total market size over time.
Fair Value Analysis Export
BAFNAPH Fair Value vs Current Price — Valuation Summary
BAFNAPH average fair value, fair value range, price gap and valuation status across 3 models: P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation.
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
BAFNAPH Fair Value Analysis — Data Sources & Coverage
Bafna Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used — 2019 financial year. For live price and a broader fundamental view, visit BAFNAPH share price screener.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is 7 years old (2019).
BAFNAPH vs Healthcare Sector Peers — P/E, P/B & Market Cap
Bafna Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Sat Kartar Life | SATKARTAR | 13.44 | 3.4 | ₹226 |
| KRM Ayurveda | KRMAYURVED | - | 4.56 | ₹545 |
| Emcure Pharmaceuticals | EMCURE | 37.24 | 7.08 | ₹34,821 |
| SMS Lifesciences | SMSLIFE | 22.27 | 1.82 | ₹354 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.